🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05360069
Recruiting Not applicable

Linear Stapler Versus Circular Stapler in Esophagojejunostomy

NCT05360069 · tracked via the Priya Life Science China tracker
Sponsor
Nanchong Central Hospital
Phase
Not applicable
Started
2020-01-01
Last updated
2026-04-02

Condition(s) studied

Postoperative ComplicationsOperative TimeHospital Costs

Investigational drug(s) / intervention(s)

Linear staplerCircular stapler

Linear stapler: Linear stapler is adopted in esophagojejunostomy

Circular stapler: Circular stapler is adopted in esophagojejunostomy

Study summary

With the development of stapler devices, various methods of esophagojejunostomy after laparoscopic total gastrectomy were evoluated. Which stapler is more advantageous has not been determined. At present, the most commonly used is linear stapler or Circular stapler in esophagojejunostomy. However, there is still a lack of reliable evidence for the selection of the two staplers. The purpose of this study is to explore the advantages of linear staper versus circular stapler in esophagojejunostomy for patients with gastric cancer who underwent total gastrectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the stomach, T1-T4 stages. 2. Eastern Cooperative Oncology Group performance status of 0 or 1. 3. Adequate organ function. Exclusion Criteria: 1. Patients had distant metastasis. 2. oesophageal invasion of more than 3 cm. 3. Borrmann type 4 or large (more than 8 cm) type 3 carcinoma. 4. Previous chemotherapy or radiation therapy for any other malignancies.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Yunhong Tian Nanchong Sichuan Recruiting

More Nanchong Central Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05360069 on ClinicalTrials.gov ↗ ← All trials in China